Phase 2a Trial of Elamipretide in FA Patients Likely to Start This Year

Phase 2a Trial of Elamipretide in FA Patients Likely to Start This Year

309957

Phase 2a Trial of Elamipretide in FA Patients Likely to Start This Year

A Phase 2a trial assessing Stealth BioTherapeutics‘ lead investigational product elamipretide in people with Friedreich’s ataxia (FA) is expected to initiate by year’s end. After feedback from the U.S. Food and Drug Administration, the company amended the trial’s design. It now aims to recruit 16 FA patients with vision loss and/or heart disease, who will receive either a high or a low dose of elamipretide. Previously, the trial planned to enroll 10 patients, and its open-label…

You must be logged in to read/download the full post.